Alternatives to Kevzara If You Can't Fill Your Prescription

Kevzara (sarilumab) is an effective biologic for rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), and polyarticular juvenile idiopathic arthritis (pJIA)—but it's not always accessible. Whether you're facing insurance delays, prior authorization denials, cost barriers, or difficulty getting it through a specialty pharmacy, there are other FDA-approved options your rheumatologist may consider. Here's a breakdown of the most important alternatives to Kevzara in 2026.

Always discuss any medication changes with your rheumatologist before switching. Your doctor knows your medical history, disease activity, and previous treatment responses—they're the right person to help you decide.

Tocilizumab (Actemra) — The Closest Alternative

Tocilizumab (brand name Actemra) works by the same mechanism as Kevzara—it blocks the IL-6 receptor and reduces inflammation. Clinical trials (the ASCERTAIN study) have compared sarilumab and tocilizumab head-to-head and found them to have comparable efficacy and safety profiles for RA.

A major advantage of tocilizumab in 2026 is that multiple biosimilars are now FDA-approved, including Tofidence (tocilizumab-bavi), Tyenne (tocilizumab-aazg), and Vegzelma (tocilizumab-vzgt). Biosimilars are typically significantly less expensive than brand-name biologics and are increasingly covered by insurance plans as preferred alternatives.

Note that tocilizumab comes in both subcutaneous (SC) and intravenous (IV) forms. The SC formulation is given weekly or every 2 weeks, while the IV form is given monthly at an infusion center. Patients who switched from tocilizumab to sarilumab in studies generally maintained disease control.

Adalimumab (Humira and Biosimilars) — A TNF Inhibitor Option

Adalimumab (Humira) is one of the most widely prescribed biologics for RA worldwide. Unlike Kevzara, which targets IL-6, adalimumab works by blocking tumor necrosis factor (TNF), another key driver of inflammation. The MONARCH trial directly compared sarilumab monotherapy to adalimumab monotherapy—sarilumab showed statistically significant superiority on some measures, but adalimumab remains a highly effective and well-studied option.

As of 2026, Humira has multiple FDA-approved biosimilars (Hadlima, Cyltezo, Hyrimoz, Yusimry, and others), which has brought the cost down significantly. Adalimumab biosimilars are given as a subcutaneous injection every 1–2 weeks and are often a first-line biologic choice before switching to IL-6 inhibitors like Kevzara.

Baricitinib (Olumiant) — An Oral JAK Inhibitor

Baricitinib (Olumiant) is a JAK (Janus kinase) inhibitor approved for moderately to severely active RA in adults who didn't respond adequately to methotrexate. Unlike Kevzara, which is a subcutaneous injection, baricitinib is an oral tablet taken once daily—a major convenience factor for many patients.

Important: JAK inhibitors including baricitinib carry FDA boxed warnings for serious infections, malignancy, thrombosis, and cardiovascular events. They are generally recommended for patients who have failed or are intolerant to one or more TNF inhibitors. Your rheumatologist will weigh these risks carefully.

Abatacept (Orencia) — A T-Cell Costimulation Blocker

Abatacept (Orencia) works by a completely different mechanism than Kevzara. Instead of blocking IL-6, it prevents T-cells from being activated—a key step in the RA inflammatory cascade. It is FDA-approved for moderately to severely active RA in adults and for polyarticular JIA in children aged 6 and older.

Abatacept is available as a monthly IV infusion or a weekly subcutaneous injection. Some patients prefer abatacept because it may have a more favorable safety profile regarding infections compared to other biologics, making it an option for patients with histories of recurring infections.

Etanercept (Enbrel) — Another TNF Inhibitor

Etanercept (Enbrel) is another TNF blocker approved for RA, psoriatic arthritis, and ankylosing spondylitis. It's given as a subcutaneous injection once or twice weekly. Etanercept has biosimilars (Eticovo, Erelzi) that may offer cost savings. It's one of the most studied biologics for RA and has a long safety track record.

For PMR Specifically: Corticosteroids and Off-Label Options

Kevzara is the only FDA-approved biologic for polymyalgia rheumatica (PMR). However, if Kevzara is not available or affordable, your rheumatologist may recommend:

Prednisone/corticosteroids — still the standard first-line treatment for PMR, though long-term use carries significant side effects

Tocilizumab (off-label for PMR) — not FDA-approved for PMR, but may be used off-label by some rheumatologists; insurance coverage for this use varies

Methotrexate (off-label for PMR) — sometimes used off-label as a steroid-sparing agent in PMR patients who cannot taper prednisone

Comparison Table: Kevzara vs. Its Alternatives

Kevzara (sarilumab): IL-6 blocker | SC injection every 2 weeks | RA, PMR, pJIA | No biosimilar | Brand only

Tocilizumab (Actemra/biosimilars): IL-6 blocker | SC or IV | RA, GCA, pJIA, sJIA | Multiple biosimilars available | Often lower cost

Adalimumab (Humira/biosimilars): TNF inhibitor | SC injection every 1–2 weeks | RA, PsA, AS and others | Many biosimilars | Often first-line biologic

Baricitinib (Olumiant): JAK inhibitor | Oral tablet daily | RA | Brand only | Boxed warning for CV/cancer risk

Abatacept (Orencia): T-cell costimulation blocker | SC weekly or IV monthly | RA, JIA | Favorable infection profile for some patients

What to Tell Your Rheumatologist

If you're unable to fill your Kevzara prescription, be specific with your rheumatologist: explain whether the barrier is cost, insurance denial, availability, or all three. If availability is the issue, medfinder can call specialty pharmacies on your behalf to find who can fill it. See our guide on how to find Kevzara in stock near you for more strategies.